Prior Authorization DRUG Guidelines

*Adcetris (brentuximab vedotin)
Effective Date: 10/22/13
Date Developed: 9/3/13 by Albert Reeves MD
Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19

ADCETRIS is a CD30-directed antibody-drug conjugate (ADC) specific for human CD30 which results in disruption of cellular microtubules and subsequent cell death.

Pre-Authorization Criteria:

Treatment of Hodgkin lymphoma after failure of at least 2 prior chemotherapy regimens (in patients ineligible for transplant) or after stem cell transplant failure; treatment of systemic anaplastic large cell lymphoma (sALCL) after failure of at least 1 prior chemotherapy regimen

Dosing:

Hodgkin lymphoma, refractory: I.V.: 1.8 mg/kg (maximum dose: 180 mg) every 3 weeks, continue until disease progression, unacceptable toxicities, or a maximum of 16 cycles

Systemic anaplastic large cell lymphoma (sALCL), refractory: I.V.: 1.8 mg/kg (maximum dose: 180 mg) every 3 weeks, continue until disease progression, unacceptable toxicities, or a maximum of 16 cycles

Note: infuse over 30 minutes using appropriate precautions for handling and disposal for hazardous materials

Note: For patients weighing >100 kg, dose should be calculated using a weight of 100 kg.

Precautions: peripheral neuropathy; neutropenia; serious infection; tumor lysis syndrome; severe nausea and vomiting; increased toxicity in patients with liver or renal impairment; Stevens-Johnson syndrome/toxic epidermal necrolysis (TEN)

Note: Black Box Warning- Progressive Multifocal Leukoencephalopathy (PML). Immunosuppression due to prior chemotherapy treatments or underlying disease may also contribute to PML development
**Drug Interactions:** CYP3A4 Inhibitors increase potency; CYP3A4 Inducers reduce potency; P-gp Inhibitors may increase chance for adverse reactions

**References:**


**Revision History:**
Date Approved by P&T Committee: 10/22/13
Date Reviewed/No Updates: 1/28/14 by C. Sanders MD
Date Approved by P&T Committee: 1/28/14
Date Reviewed/Updated: 1/8/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/Updated: 1/13/16 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/23/18
Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/23/18</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/22/19</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>